CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy

In this phase II study, TAK-007, an off-the-shelf allogeneic CD19 CAR NK-cell therapy expressing IL-15, demonstrates encouraging response rates, rapid treatment availability, and an excellent safety profile in heavily pretreated B-cell lymphoma, including post-CAR-T patients, albeit with limited durability. These findings, supported by integrated translational analyses, provide important mechanistic insights into CAR-NK biology that may guide future optimization and bring this approach closer to broader clinical application. See related article by Darrah et al., p. XX .